Ramucirumab
15608
Phase 2 small_molecule completed
Quick answer
Ramucirumab for Gastric Adenocarcinoma is a Phase 2 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Gastric Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed